​

Bio-Techne (TECH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TECH Stock Forecast

Bio-Techne (TECH) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $82.33, with a high of $84.00 and a low of $80.00. This represents a 14.62% increase from the last price of $71.83.

$60 $65 $70 $75 $80 $85 High: $84 Avg: $82.33 Low: $80 Last Closed Price: $71.83

TECH Stock Rating

Bio-Techne stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (57.14%), 2 Hold (28.57%), 1 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 2 4 Strong Sell Sell Hold Buy Strong Buy

TECH Forecast vs Benchmarks

TypeNameUpside
StockBio-Techne14.62%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$84.00$82.33
Last Closing Price$71.83$71.83$71.83
Upside/Downside-16.94%14.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25393--15
Dec, 24393--15
Nov, 24493--16
Oct, 24594--18
Sep, 24594--18
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Catherine SchulteRobert W. Baird$84.00$76.0210.50%16.94%
Oct 30, 2024Paul KnightKeyBanc$80.00$76.025.24%11.37%
Aug 16, 2024Sung Ji NamScotiabank$83.00$74.1911.87%15.55%
Dec 14, 2022Deutsche Bank$100.00$86.9814.97%39.22%
Dec 12, 2022Citigroup$100.00$80.7323.87%39.22%
Dec 07, 2022RBC Capital$89.00$80.6710.33%23.90%
Dec 05, 2022Stephens$105.00$82.4427.37%46.18%
May 05, 2022Paul KnightKeyBanc$125.00$98.9626.31%74.02%
Apr 25, 2022Wells Fargo$92.50$100.75-8.19%28.78%
May 06, 2021Patrick B DonnellyCitigroup$106.25$102.453.71%47.92%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024KeyBancOverweightOverweighthold
Aug 16, 2024ScotiabankSector OutperformSector Outperformhold
Aug 13, 2024RBC CapitalSector PerformSector Performhold
May 22, 2024Deutsche BankBuyBuyhold
May 22, 2024CitigroupBuyNeutraldowngrade
May 02, 2024ScotiabankOutperformOutperformhold
Feb 02, 2024RBC CapitalSector PerformSector Performhold
Aug 28, 2023William BlairOutperforminitialise
Dec 14, 2022Deutsche BankBuyinitialise
Dec 12, 2022CitigroupBuyupgrade

Financial Forecast

EPS Forecast

Jun 20 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$1.50$0.91$1.73$1.81$1.07----
Avg Forecast$1.07$1.64$1.98$2.00$1.78$1.88$2.18$2.49-
High Forecast$1.05$1.61$1.94$1.96$1.76$1.83$2.04$2.28-
Low Forecast$1.09$1.66$2.01$2.05$1.80$1.92$2.35$2.80-
Surprise %40.19%-44.51%-12.63%-9.50%-39.89%----

Revenue Forecast

$500M $800M $1B $1B $2B $2B Jun 20 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$738.69M$931.03M$1.11B$1.14B$1.16B----
Avg Forecast$726.77M$924.08M$1.10B$1.14B$1.16B$1.22B$1.33B$1.48B$1.86B
High Forecast$715.00M$909.11M$1.09B$1.12B$1.14B$1.21B$1.31B$1.47B$1.83B
Low Forecast$735.17M$934.77M$1.12B$1.16B$1.18B$1.23B$1.36B$1.48B$1.89B
Surprise %1.64%0.75%0.05%-0.54%0.02%----

Net Income Forecast

$0 $100M $200M $300M $400M $500M Jun 20 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$229.30M$140.41M$272.05M$285.26M$168.10M----
Avg Forecast$198.54M$128.87M$196.47M$321.71M$150.68M$300.71M$352.85M$408.30M-
High Forecast$158.83M$103.09M$157.18M$315.03M$120.54M$293.42M$328.15M$365.77M-
Low Forecast$238.25M$154.64M$235.76M$329.07M$180.82M$308.01M$377.54M$450.83M-
Surprise %15.49%8.96%38.47%-11.33%11.56%----

TECH Forecast FAQ

Is Bio-Techne stock a buy?

Bio-Techne stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Techne is a favorable investment for most analysts.

What is Bio-Techne's price target?

Bio-Techne's price target, set by 7 Wall Street analysts, averages $82.33 over the next 12 months. The price target range spans from $80 at the low end to $84 at the high end, suggesting a potential 14.62% change from the previous close price of $71.83.

How does Bio-Techne stock forecast compare to the average forecast of its sector, industry, and investment themes?

Bio-Techne stock forecast shows a 14.62% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Bio-Techne over the past three months?

  • January 2025: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 25.00% Strong Buy, 56.25% Buy, 18.75% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Techne’s EPS forecast?

Bio-Techne's average annual EPS forecast for its fiscal year ending in June is 1.88 for 2025, a 75.70% increase from the reported $1.07 in 2024. The prediction for 2026 is $2.18, $2.49 for 2027, and $0 for 2028.

What is Bio-Techne’s revenue forecast?

Bio-Techne's average annual revenue forecast for its fiscal year ending in June is $1.22B for 2025, a 5.28% increase from the reported $1.16B in 2024. The forecast for 2026 is $1.33B, $1.48B for 2027, and $1.86B for 2028.

What is Bio-Techne’s net income forecast?

For its fiscal year ending in June, Bio-Techne's average annual net income forecast is $300.71M for 2025, reflecting an 78.88% increase from the reported $168.1M in 2024. The projection for 2026 is $352.85M, $408.3M for 2027, and $0 for 2028.